Skip to main content

Nasal IL-16 and MIP-1 α in Late-Phase Allergic Response

Buy Article:

$31.50 plus tax (Refund Policy)

Late-phase response in allergic rhinitis is characterized by tissue eosinophilia and influx of CD4+ T-cells. 1L-16 and MIP-1α are highly chemotactic on T-cells and on eosinophils. Both IL-16 and MIP-1α have been demonstrated to be up-regulated after challenge in the late-phase response in various atopic conditions other than allergic rhinitis. The aim of our study was to determine the expression of IL-16 and MIP-1α in nasal secretions following allergen challenge in allergic rhinitis, and to compare these with characteristic late-phase mediators such as IL-5 and ECP. Nasal secretions of 14 allergic volunteers challenged intranasally by their specific allergen were studied from 20 minutes to 8 hours after allergen challenge. Nasal secretions were analyzed by routine ELISA for IL-16, MIP-1α, IL-5, and ECP. IL-16 and MIP-1α increased significantly in nasal secretions of challenged allergic patients in the late-phase response. IL-16 revealed highest amounts 5 hours after challenge, whereas MIP-1α peaked at 7 hours. Both correlated significantly (r = 0.917, p < 0.05) at 6 hours. IL-5 and ECP peaked between 6 and 8 hours and correlated significantly (r = 0.951, p < 0.01) at 6 hours as well. Our data demonstrate that IL-16 and MIP-1α are expressed in the late-phase response in allergic rhinitis in a more or less similar kinetic like IL-5 and ECP. They are suggested to be responsible for the observed influx of eosinophils (IL-5, IL-16, and MIP-1α) and CD4+ T-cells (IL-16 and MIP-1α) into the challenged allergic mucosa.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Document Type: Research Article

Publication date: 2001-05-01

More about this publication?
  • Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.

    The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.

    Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.

    Articles marked "F" offer free full text for personal noncommercial use only.

    The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Information for Advertisers
  • Reprint Requests
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more